- Home
- PEBK vs CABA Comparison
PEBK vs CABA Comparison
Compare PEBK & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEBK
- CABA
- Stock Information
- Founded
- PEBK 1912
- CABA 2017
- Country
- PEBK United States
- CABA United States
- Employees
- PEBK N/A
- CABA N/A
- Industry
- PEBK Major Banks
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PEBK Finance
- CABA Health Care
- Exchange
- PEBK Nasdaq
- CABA Nasdaq
- Market Cap
- PEBK 155.1M
- CABA 174.7M
- IPO Year
- PEBK N/A
- CABA 2019
- Fundamental
- Price
- PEBK $32.35
- CABA $2.16
- Analyst Decision
- PEBK
- CABA Strong Buy
- Analyst Count
- PEBK 0
- CABA 8
- Target Price
- PEBK N/A
- CABA $12.75
- AVG Volume (30 Days)
- PEBK 4.7K
- CABA 1.4M
- Earning Date
- PEBK 10-20-2025
- CABA 11-13-2025
- Dividend Yield
- PEBK 3.02%
- CABA N/A
- EPS Growth
- PEBK 4.77
- CABA N/A
- EPS
- PEBK 3.11
- CABA N/A
- Revenue
- PEBK $84,131,000.00
- CABA N/A
- Revenue This Year
- PEBK N/A
- CABA N/A
- Revenue Next Year
- PEBK N/A
- CABA N/A
- P/E Ratio
- PEBK $10.11
- CABA N/A
- Revenue Growth
- PEBK 6.23
- CABA N/A
- 52 Week Low
- PEBK $23.74
- CABA $0.99
- 52 Week High
- PEBK $33.31
- CABA $5.46
- Technical
- Relative Strength Index (RSI)
- PEBK 64.51
- CABA 72.03
- Support Level
- PEBK $31.44
- CABA $1.63
- Resistance Level
- PEBK $31.78
- CABA $1.74
- Average True Range (ATR)
- PEBK 0.44
- CABA 0.14
- MACD
- PEBK -0.03
- CABA 0.05
- Stochastic Oscillator
- PEBK 100.00
- CABA 94.30
About PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.